Eaf151-Change In Relative Cerebral Blood Volume As A Biomarker For Early Response To Bevacizumab In Patients With Recurrent Glioblastoma
Posted Date: Jun 11, 2019
- Investigator: Rekha Chaudhary
- Specialties: Cancer, Oncology
- Type of Study: Drug
The goal of this study is to determine whether binary changes (increase vs. decrease) in normalized rCBV within enhancing tumor from baseline to 2 weeks after initiation of anti-angiogenic therapy is associated with overall survival.
Criteria:
To Be Eligible: Patient Must Be At 18+ Years Of Age And Diagnosed With A Glioblastoma Or Gliosarcoma, Nonpregnant And Nonbreastfeeding, No Previous Immunotherapies
Keywords:
Brain Cancer, Glioblastoma
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com